Md Medical Group Invest Net Income surged on 28.8% in 2016
20 Mar 2017 • About Md Medical Group Invest (
$MDMG) • By InTwits
Md Medical Group Invest reported FY2016 financial results today. Overall the company's long term financial model is characterised by the following facts: It operates with high leverage: Net Debt/EBITDA is 0.3x while industry average is -0.4x.
Below you can find a comprehensive analysis of the key data driving the company's performance and stock price.
Md Medical Group Invest ($MDMG) key annual financial indicators
| mln. RUB | 2012 | 2013 | 2014 | 2015 | 2016 | 2016/2015 |
|---|
P&L
|
|---|
| Revenue | 4,061 | 5,673 | 7,201 | 9,507 | 12,180 | 28.1% |
| Gross Profit | 2,048 | 2,283 | 2,971 | 3,589 | | -100.0% |
| EBITDA | 1,694 | 1,586 | 2,083 | 2,656 | | -100.0% |
| Net Income | 1,399 | 636 | 1,196 | 1,604 | 2,066 | 28.8% |
Balance Sheet
|
|---|
| Cash | 2,583 | 3,273 | 891 | 1,774 | | -100.0% |
| Short Term Debt | 263 | 1,238 | 1,739 | 1,163 | | -100.0% |
| Long Term Debt | 2,696 | 2,380 | 3,251 | 2,300 | | -100.0% |
Cash flow
|
|---|
| Capex | 2,646 | 2,430 | 3,126 | 780 | | -100.0% |
Ratios
|
|---|
| Revenue growth | 39.7% | 39.7% | 26.9% | 32.0% | 28.1% | |
| EBITDA growth | 31.1% | -6.4% | 31.3% | 27.5% | | |
| Gross Margin | 50.4% | 40.3% | 41.3% | 37.7% | | -37.7% |
| EBITDA Margin | 41.7% | 28.0% | 28.9% | 27.9% | 0.0% | -27.9% |
| Net Income Margin | 34.5% | 11.2% | 16.6% | 16.9% | 17.0% | 0.1% |
| CAPEX, % of revenue | 65.2% | 42.8% | 43.4% | 8.2% | | -8.2% |
| ROIC | 19.9% | 9.5% | 11.0% | 11.8% | | -11.8% |
| ROE | 25.8% | 7.4% | 12.9% | 15.4% | | -15.4% |
| Net Debt/EBITDA | 0.2x | 0.2x | 2.0x | 0.6x | | -0.6x |
Revenue and profitability
The company's Revenue surged on 28.1% in FY2016.
Net Income marign showed almost no change in FY2016.
Appendix 1: Peers in Health Care Equipment & Services
Below we provide Md Medical Group Invest benchmarking against other companies in Health Care Equipment & Services industry for the last 5 years. We show data for the top-5 companies by key financial metric together with the median value for all the companies in the industry.
Top companies by Revenue growth, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Puricore ($PURI) | 11.3% | -33.6% | -45.5% | 36.5% | |
| Tristel ($TSTL) | | -3.5% | 27.6% | 13.8% | 11.5% |
| Lifeline Scientific Inc ($LSIC) | 18.7% | 10.2% | 6.0% | 11.8% | |
| Synergy Health ($SYR) | 8.6% | 15.8% | 5.3% | 7.5% | |
| Omega Diagnostics Group ($ODX) | | 1.2% | 2.9% | 4.4% | 5.3% |
| |
|---|
| Median (10 companies) | 11.3% | 3.2% | 5.2% | 2.6% | 2.2% |
|---|
| Md Medical Group Invest ($MDMG) | | 39.7% | 26.9% | 32.0% | 28.1% |
Top companies by Gross margin, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Smith & Nephew ($SN.) | 74.1% | 74.7% | 74.8% | 75.3% | 72.8% |
| Tristel ($TSTL) | 67.9% | 66.4% | 69.8% | 69.5% | 73.4% |
| Omega Diagnostics Group ($ODX) | 63.0% | 62.6% | 63.6% | 63.4% | 63.8% |
| Immunodiagnostic Systems Hldgs ($IDH) | 74.7% | 73.1% | 68.1% | 62.5% | 58.6% |
| Lifeline Scientific Inc ($LSIC) | 60.6% | 59.8% | 61.3% | 60.2% | |
| |
|---|
| Median (10 companies) | 57.8% | 56.5% | 57.9% | 58.7% | 58.6% |
|---|
| Md Medical Group Invest ($MDMG) | 50.4% | 40.3% | 41.3% | 37.7% | |
Top companies by EBITDA margin, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Synergy Health ($SYR) | 26.0% | 26.4% | 25.8% | 24.3% | |
| Immunodiagnostic Systems Hldgs ($IDH) | | 35.3% | 34.1% | 23.6% | -77.1% |
| Smith & Nephew ($SN.) | 27.8% | 26.9% | 25.2% | 23.1% | 26.0% |
| Tristel ($TSTL) | 17.0% | 13.7% | 20.1% | 22.9% | 20.7% |
| Abbott Laboratories ($ABT) | 21.8% | 19.6% | 20.5% | 21.3% | 22.6% |
| |
|---|
| Median (10 companies) | 17.0% | 14.9% | 19.1% | 19.5% | 12.0% |
|---|
| Md Medical Group Invest ($MDMG) | 41.7% | 28.0% | 28.9% | 27.9% | |
Top companies by CAPEX/Revenue, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Synergy Health ($SYR) | 15.2% | 13.2% | 10.3% | 15.1% | |
| Smith & Nephew ($SN.) | 6.4% | 7.8% | 8.1% | 7.7% | 8.4% |
| Ekf Diagnostics Holdings ($EKF) | 3.7% | 3.7% | 2.8% | 7.6% | 3.3% |
| Puricore ($PURI) | 2.4% | 3.2% | 15.4% | 7.3% | |
| Immunodiagnostic Systems Hldgs ($IDH) | 5.7% | 5.3% | 4.4% | 6.3% | 4.7% |
| |
|---|
| Median (10 companies) | 5.7% | 4.5% | 5.2% | 6.1% | 4.7% |
|---|
| Md Medical Group Invest ($MDMG) | 65.2% | 42.8% | 43.4% | 8.2% | |
Top companies by ROIC, %
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Lifeline Scientific Inc ($LSIC) | 1.9% | 11.2% | 11.7% | 24.0% | |
| Tristel ($TSTL) | 6.5% | 3.5% | 15.9% | 20.1% | 17.5% |
| Smith & Nephew ($SN.) | 22.0% | 18.6% | 14.7% | 11.1% | 14.4% |
| Abbott Laboratories ($ABT) | 4.3% | 5.3% | 8.3% | 9.4% | 8.6% |
| Synergy Health ($SYR) | 8.0% | 8.5% | 9.1% | 9.1% | |
| |
|---|
| Median (10 companies) | 4.3% | 5.3% | 8.7% | 6.7% | 3.3% |
|---|
| Md Medical Group Invest ($MDMG) | 19.9% | 9.5% | 11.0% | 11.8% | |
Top companies by Net Debt / EBITDA
| Top 5 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|
| Synergy Health ($SYR) | 2.1x | 1.9x | 1.5x | 1.6x | |
| Smith & Nephew ($SN.) | 0.3x | 0.2x | 1.4x | 1.3x | 1.3x |
| Abbott Laboratories ($ABT) | 2.1x | 0.8x | 0.9x | 0.9x | 0.7x |
| Lifeline Scientific Inc ($LSIC) | -4.4x | -0.6x | -0.3x | -1.0x | |
| Omega Diagnostics Group ($ODX) | 0.1x | 0.7x | -1.8x | -1.0x | -0.7x |
| |
|---|
| Median (8 companies) | 0.1x | -0.2x | -0.3x | -1.0x | -0.6x |
|---|
| Md Medical Group Invest ($MDMG) | 0.2x | 0.2x | 2.0x | 0.6x | |
